FY2023 · ended Dec 31, 2023 · Revenue $0, -100.0% YoY · Filed Mar 20, 2025
SELLAS Life Sciences Group, Inc. (SLS) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Jun 30, 2026 it held $138.3 million in cash and investments and $737,000 in total debt.
Revenue
$0
-100.0% vs prior year
Net income (TTM)
$-32.46M
-23.6% vs year-ago TTM
Operating cash flow (TTM)
$-28.42M
+9.4% vs year-ago TTM
Free cash flow
$-11.86M
EPS (TTM)
$-0.21
+33.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
179.58M
+97.7% vs prior year
Net cash
$137.61M
as of Jun 30, 2026
Operating margin
-4195.0%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1390478
- Former names
- GALENA BIOPHARMA, INC. (until Dec 15, 2017); Galena Biopharma, Inc. (until Dec 15, 2017); RXI PHARMACEUTICALS CORP (until Sep 21, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.0M | $7.6M |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M |
| Diluted EPS | -$0.25 | -$0.50 | -$1.34 | -$2.13 | -$1.34 |
| Operating cash flow | -$28.4M | -$35.4M | -$31.4M | -$23.8M | -$26.0M |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M |
| Stockholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M |
| Cash and investments | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M |
| Total debt | $1.0M | $1.0M | $906,000 | $945,000 | $808,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Jul 27, 2026 | Jul 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 25, 2026 | Jun 24, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2026 | Jun 16, 2026 |
| 8-K |
Current report
Other events
|
Jun 2, 2026 | Jun 2, 2026 |
All 1002 SELLAS Life Sciences Group, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.